Lack of effect of intrarectal XXXX for @entity158 control during transrectal prostate biopsy: a randomized prospective study.

@entity1 @entity263 @entity3303 @entity158 @entity1486
INTRODUCTION AND OBJECTIVES: Transrectal ultrasound guided biopsy is an essential part in the diagnosis of @entity263 . Although this procedure is well tolerated by most @entity1 , sometimes it can result in some uneasiness. In this randomised double-blind placebo controlled study, we evaluated the effectiveness of intrarectal @entity3303 during TRUS guided biopsy. MATERIALS AND METHODS: 100 consecutive eligible @entity1 who had elevated total @entity1486 (tPSA) and/or abnormal digital rectal examination (DRE) were included into this study. @entity1 were randomised into two groups. Group I received 20 cc of 2% intrarectal @entity3303 20 minutes before transrectal ultrasound guided biopsy and Group II received same amount of serum physiologic. @entity158 was assessed using a 10 point modified visual analog scale. RESULTS: Mean @entity1 age was 65.5+/-2.5 and 64.5+/-11.5 years, mean tPSA was 12.3+/-3.6 and 11.3+/-1.7 ng/ml, mean biopsy duration was 6.8+/-2.5 and 6.6+/-2.2 minutes, mean @entity158 score during transrectal ultrasound guided biopsy was 4.8+/-2.2 and 4.4+/-2.1 in Groups I and II, respectively. No statistically significant difference was observed with respect to age, tPSA, mean biopsy duration and @entity158 score between these groups. There was only one @entity1 who could not tolerate the procedure at all, and he was paradoxically in the @entity3303 group. CONCLUSION: The use of intrarectal @entity3303 is not superior to placebo during transrectal prostate biopsy for @entity158 control.
